Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT04421560 2026-02-20

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Phase 1/2 Recruiting

37 enrolled

Neoplasms, Recurrence

NCT06052839 2026-02-09

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

Phase 2 Recruiting

15 enrolled

Recurrence

NCT05084430 2026-01-22

Study of Pembrolizumab and M032 (NSC 733972)

Phase 1/2 Recruiting

28 enrolled

CNSSarcoma

Astrocytoma, Glioblastoma, Recurrence, Gliosarcoma

NCT05359445 2025-09-09

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

Phase 1 Recruiting

95 enrolled

Neoplasms, Recurrence

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Phase 2 Recruiting

32 enrolled

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05595447 2025-03-12

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Phase 2/3 Recruiting

20 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT06670911 2025-02-24

ACCESS-I

Phase 2 Recruiting

44 enrolled

Recurrence

NCT06016920 2024-12-17

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

Phase 1/2 Recruiting

51 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT05635344 2024-04-17

A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia

Phase 2 Recruiting

20 enrolled

Gynecologic

Recurrence, Gestational Trophoblastic Disease

NCT04510636 2024-03-22

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Phase 2 Recruiting

37 enrolled

Neoplasms, Recurrence

Clinical Trials

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

AHEAD-MERIT

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

Study of Pembrolizumab and M032 (NSC 733972)

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

ACCESS-I

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma